The global central nervous system therapeutics market is estimated to be USD 144.3 Million in 2024 and is expected to reach USD 431.0 Million by 2035, with a CAGR of 10.46% during the forecast period 2025-2035. The market will grow as a result of factors such as the rising prevalence of neurological disorders, improvements in drug development and approvals, increased investments in R&D, growing telemedicine and digital therapeutics adoption, and growing use of personalized medicine.
Biopharmaceutical companies are increasingly concentrating on the development of novel therapeutics for the central nervous system (CNS), including disease-modifying drugs, biologics, and gene therapies. For instance, in March 2024, Ultomiris received FDA approval as the first long-acting C5 complement inhibitor specifically for treating adults with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), showcasing its effectiveness in significantly reducing relapses. This trend reflects a robust commitment within the industry to advance innovative treatment modalities for CNS disorders.
By disease, the mental health therapeutics segment accounted for the highest revenue-grossing segment in the global central nervous system therapeutics market in 2024 owing to the increasing prevalence of mental health disorders such as depression, anxiety, and schizophrenia, along with growing awareness and acceptance of mental health treatments. For instance, in May 2024, AC Immune and Takeda signed an exclusivity contract for the Alzheimer's immunotherapy ACI-24.060, which included an upfront payment of USD 100 million and possible milestones of USD 2.1 Million. Additionally, the neurodegenerative diseases segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of conditions like Alzheimer's and Parkinson's disease, advancements in disease-modifying therapies, and a growing aging population that is more susceptible to these disorders.
By drug class, the CNS stimulants segment accounted for the highest revenue-grossing segment in the global central nervous system therapeutics market in 2024 owing to the growing demand for ADHD treatments and the increasing use of stimulants for managing attention-deficit hyperactivity disorder in both children and adults. For instance, in October 2024, AbbVie and Aliada Therapeutics announced a final deal whereby AbbVie will buy Aliada, a biotechnology company developing treatments for difficult central nervous system (CNS) diseases using a novel blood-brain barrier (BBB)-crossing technology. This delivery technique is being used by Aliada's flagship experimental asset, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody that is being developed to treat Alzheimer's disease. Additionally, the anticonvulsants segment is predicted to grow at the fastest CAGR during the forecast period owing to its widespread application in treating epilepsy, bipolar disorder, and neuropathic pain, along with the development of new-generation anticonvulsants with fewer side effects and improved efficacy.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global central nervous system therapeutics market in 2024 owing to the increasing number of hospital admissions for severe neurological and psychiatric conditions, coupled with the availability of specialized CNS treatments in hospital settings. For instance, as part of 2024 HOPE Therapeutics, Inc., a medical and technology-driven company, NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP) has signed a non-binding Letter of Intent (LOI) to purchase its first Interventional Psychiatry Clinics in Florida. These clinics are considered excellent achievers and will be the company's Florida expansion base. Additionally, the retail pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding reach of retail pharmacy chains, rising over-the-counter availability of CNS medications, and the growing preference for outpatient treatment, particularly in emerging markets.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of neurological and mental health disorders, significant investments in R&D, and the presence of key market players driving the adoption of innovative CNS therapies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly increasing healthcare spending, growing awareness of neurological and psychiatric disorders, expanding access to advanced treatments, and a large, aging population that is more susceptible to neurodegenerative conditions. For instance, Biogen reallocated its resources in January 2024, putting LEQEMBI ahead of ADUHELM, concentrating on developing novel Alzheimer's medicines, and stopping the development of ADUHELM because of safety and efficacy issues.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Biopharmaceutical companies are increasingly concentrating on the development of novel therapeutics for the central nervous system (CNS), including disease-modifying drugs, biologics, and gene therapies. For instance, in March 2024, Ultomiris received FDA approval as the first long-acting C5 complement inhibitor specifically for treating adults with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), showcasing its effectiveness in significantly reducing relapses. This trend reflects a robust commitment within the industry to advance innovative treatment modalities for CNS disorders.
By disease, the mental health therapeutics segment accounted for the highest revenue-grossing segment in the global central nervous system therapeutics market in 2024 owing to the increasing prevalence of mental health disorders such as depression, anxiety, and schizophrenia, along with growing awareness and acceptance of mental health treatments. For instance, in May 2024, AC Immune and Takeda signed an exclusivity contract for the Alzheimer's immunotherapy ACI-24.060, which included an upfront payment of USD 100 million and possible milestones of USD 2.1 Million. Additionally, the neurodegenerative diseases segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of conditions like Alzheimer's and Parkinson's disease, advancements in disease-modifying therapies, and a growing aging population that is more susceptible to these disorders.
By drug class, the CNS stimulants segment accounted for the highest revenue-grossing segment in the global central nervous system therapeutics market in 2024 owing to the growing demand for ADHD treatments and the increasing use of stimulants for managing attention-deficit hyperactivity disorder in both children and adults. For instance, in October 2024, AbbVie and Aliada Therapeutics announced a final deal whereby AbbVie will buy Aliada, a biotechnology company developing treatments for difficult central nervous system (CNS) diseases using a novel blood-brain barrier (BBB)-crossing technology. This delivery technique is being used by Aliada's flagship experimental asset, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody that is being developed to treat Alzheimer's disease. Additionally, the anticonvulsants segment is predicted to grow at the fastest CAGR during the forecast period owing to its widespread application in treating epilepsy, bipolar disorder, and neuropathic pain, along with the development of new-generation anticonvulsants with fewer side effects and improved efficacy.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global central nervous system therapeutics market in 2024 owing to the increasing number of hospital admissions for severe neurological and psychiatric conditions, coupled with the availability of specialized CNS treatments in hospital settings. For instance, as part of 2024 HOPE Therapeutics, Inc., a medical and technology-driven company, NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP) has signed a non-binding Letter of Intent (LOI) to purchase its first Interventional Psychiatry Clinics in Florida. These clinics are considered excellent achievers and will be the company's Florida expansion base. Additionally, the retail pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding reach of retail pharmacy chains, rising over-the-counter availability of CNS medications, and the growing preference for outpatient treatment, particularly in emerging markets.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of neurological and mental health disorders, significant investments in R&D, and the presence of key market players driving the adoption of innovative CNS therapies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly increasing healthcare spending, growing awareness of neurological and psychiatric disorders, expanding access to advanced treatments, and a large, aging population that is more susceptible to neurodegenerative conditions. For instance, Biogen reallocated its resources in January 2024, putting LEQEMBI ahead of ADUHELM, concentrating on developing novel Alzheimer's medicines, and stopping the development of ADUHELM because of safety and efficacy issues.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Report Scope:
- Base Year: 2024
- Forecast Period: 2025-2035
- Study Coverage
- Market Forecast by Disease, Drug Class, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Central Nervous System Therapeutics Market Report 2024 - 2035
Central Nervous System Therapeutics Market Analysis & Forecast by Disease 2024 - 2035 (Revenue USD Mn)
- Neurovascular Diseases
- CNS Trauma
- Mental Health
- Anxiety Disorders
- Epilepsy
- Mood Disorders
- Psychotic Disorders
- Others
- Neurodegenerative Diseases
- Alzheimer’s Disease
- Parkinsosn’s Disease
- Multiple Sclerosis
- Huntington’s Disease
- Amytrophic Lateral Sclerosis
- Others
- Infectious Diseases
- CNS Cancer
- Others
Central Nervous System Therapeutics Market Analysis & Forecast by Drug Class 2024 - 2035 (Revenue USD Mn)
- Anesthetics
- Anticonvulsants
- Antiemetics
- CNS Stimulants
- Pain Relievers
- Others
Central Nervous System Therapeutics Market Analysis & Forecast by Distribution Channel 2024 - 2035 (Revenue USD Mn)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Central Nervous System Therapeutics Market Analysis & Forecast by Region 2024 - 2035 (Revenue USD Mn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Central Nervous System Therapeutics Market: Disease Estimates & Trend Analysis
8. Central Nervous System Therapeutics Market: Drug Class Estimates & Trend Analysis
9. Central Nervous System Therapeutics Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Central Nervous System Therapeutics Market
12. Europe Global Central Nervous System Therapeutics Market
13. Asia Pacific Global Central Nervous System Therapeutics Market
14. Latin America Global Central Nervous System Therapeutics Market
15. MEA Global Central Nervous System Therapeutics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson (Janssen Pharmaceuticals)
- Roche Holding AG
- Novartis AG
- Eli Lilly and Company
- Bristol-Myers Squibb
- Sanofi
- AbbVie Inc.
- Merck & Co., Inc.
- Biogen Inc.
- AstraZeneca PLC
- GlaxoSmithKline (GSK)
- Amgen Inc.
- H. Lundbeck A/S
- Teva Pharmaceutical Industries Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 144.3 Million |
| Forecasted Market Value ( USD | $ 431 Million |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
